OncoMatch/Clinical Trials/NCT07339059
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Is NCT07339059 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Sacituzumab govitecan and Atezolizumab for small cell lung cancer ( sclc ).
Treatment: Sacituzumab govitecan · Atezolizumab · Durvalumab — The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV, III
extensive stage at diagnosis or locally advanced disease and unable to receive curative intent radiation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
must have received at least four cycles of platinum plus etoposide
Must have received: anti-PD-L1 therapy (atezolizumab, durvalumab)
at least 2-3 cycles of atezolizumab/ Durvalumab
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Exception: within 12 months of the study
Patients with prior exposure to anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, CTLA-4) within 12 months of the study is not allowed.
Lab requirements
Blood counts
adequate organ function - bone marrow
Kidney function
adequate organ function - kidney; exclusion: significant renal impairment requiring dialysis
Liver function
adequate organ function - liver; exclusion: hepatic impairment with end-stage liver disease
Adequate organ function - bone marrow, kidney, and liver. Exclusion: significant renal impairment requiring dialysis or hepatic impairment with end-stage liver disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Henry Ford Cancer- Detroit · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify